Reading this on a mobile device? Try our optimized mobile version here: http://r.smartbrief.com/resp/emmBCfbwocfDsrwFUNpo

March 6, 2013
More than 2,700 companies nationwide are saving on lab supplies, shipping, news distribution, office products and more through the BIO Business Solutions cost-savings program. Find out how.

The news summaries appearing in BIO SmartBrief are based on original information from news organizations and are produced by SmartBrief, Inc., an independent e-mail newsletter publisher. The information is not compiled or summarized by BIO. Questions and comments should be directed to SmartBrief at bio@smartbrief.com.

  Today's Top Story 
  • Humira, Advair, Rituxan lead list of best-selling drugs in 2012
    AbbVie's Humira, or adalimumab, topped this list of last year's 20 best-selling drugs based on publicly available figures. GlaxoSmithKline's Advair came in second, followed by Roche Holding's Rituxan, or rituximab. Rounding out the top 10 were Sanofi's Lantus, Roche's Herceptin, AstraZeneca's Crestor, Johnson & Johnson's Remicade, Roche's Avastin, Eli Lilly and Co.'s Cymbalta, and Sanofi and Bristol-Myers Squibb's Plavix. Genetic Engineering & Biotechnology News (3/5) LinkedInFacebookTwitterEmail this Story
Panel Gives Thumbs-Down to Depomed's Hot Flash Drug
The modest reduction in menopause-related vasomotor symptoms (VMS) recorded in three Phase III trials was not sufficient to warrant the side-effect risk associated with gabapentin, according to the FDA's Reproductive Health Drugs Advisory Committee, which voted 12-2 to recommend against Depomed Inc.'s Sefelsa (formerly Serada). Find out the details.

  Health Care & Policy 
  • White House to Congress: Exempt FDA user fees from sequester
    The Obama administration urged Congress to allow the FDA to spend $41 billion in drugmaker user fees. The sequestration law limits the amount of fee-derived funds that the agency can spend, and experts warn that the agency will not be able to approve new drug and device applications quickly if the funds are subject to sequestration. Sequestration will slow progress toward cures and cost thousands of researchers their jobs, the White House warned. PharmaTimes (U.K.) (3/5), The Philadelphia Inquirer (2/28) LinkedInFacebookTwitterEmail this Story
  • FDA accepts Biogen Idec's hemophilia B drug for review
    The FDA has set a timeline to review Biogen Idec's biologics license application for its recombinant factor IX Fc fusion protein as a therapy for patients with hemophilia B. The drug is among a new class of long-lasting clotting factor therapies in the pipeline for hemophilia B. Boston Herald (3/4) LinkedInFacebookTwitterEmail this Story
Reach Biopharmaceutical Decision-Makers with SmartBrief
You read SmartBrief, but did you know that SmartBrief publishes more than 30 unique e-newsletters for life science and health care professionals? SmartBrief delivers an engaged audience of more than a half-million business leaders, driving best-in-class click through rates and consistent reader engagement. Find out if we're reaching your target audience or contact us.
  Company & Financial News 
  • EKF moves to make inroads in molecular Dx market
    EKF Diagnostics has agreed to acquire 360 Genomics, which specializes in mutation detection technology, for $2.4 million worth of company stock and as much as $12.1 million in milestone cash payments. The deal will allow EKF to expand its point-of-care testing portfolio as well as make inroads in the molecular diagnostics arena. Clinica (subscription required) (3/4) LinkedInFacebookTwitterEmail this Story
Get Creative: 10 Ways to Think Outside the Box
No matter your business, smart solutions come from out-of-the-box thinking. We all know creativity is king, but are you doing all you can to inspire and encourage creativity in your staff? Read the article and learn 10 ways to inspire creativity at your office.

  Food & Agriculture 
 
Clinical Trial Data Transparency Forum: Expert insights
Hear industry and academic thought leaders - from Duke Clinical Research Institute, GlaxoSmithKline, Eli Lilly and more - share valuable insight on their clinical trial data transparency and sharing initiatives. This video covers a number of key perspectives and trends.

  Industrial & Environmental 
  • Supporters hopeful of biofuel bill's passage in Minn.
    Biofuel supporters are hopeful that Minnesota lawmakers will adopt legislation seeking to expand the market for E15, biobutanol and other renewable fuels in the state. Unlike measures in other states, the bill would boost support for both corn-based ethanol and next-generation biofuels, said Brian Kletscher, CEO of Highwater Ethanol. EthanolProducer.com (3/5) LinkedInFacebookTwitterEmail this Story
The Buzz(CORPORATE ANNOUNCEMENTS)

Interested in learning more about advertising in BIO SmartBrief? Contact Meryl Harold at (202) 407-7828 or mharold@smartbrief.com. 

  News from BIO 
  • Ship with FedEx
    FedEx is now offering member companies discounts of up to 35% off select FedEx services, both U.S. and international services. The BIO program with FedEx is one of the many cost-savings programs offered by BIO through its Business Solutions program. There is no charge for BIO member companies to participate in any of the BIO Business Solutions programs -- it is a benefit of membership. Learn more about the BIO and FedEx program. LinkedInFacebookTwitterEmail this Story
Learn more about BIO ->Conferences  |  Join BIO  |  Media  |  Issues  |  Industry

  SmartQuote 
Every time you spend money, you're casting a vote for the kind of world you want."
--Anna Lappé,
American writer, speaker and activist


LinkedInFacebookTwitterEmail this Story

 
 
Subscriber Tools
     
Print friendly format | Web version | Search past news | Archive | Privacy policy

Advertise
Account Director:  Meryl Harold (202) 407-7828
 
Read more at SmartBrief.com
A powerful website for SmartBrief readers including:
 
 
 Recent BIO SmartBrief Issues:   Lead Editor:  Tom Parks
     
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
 
 
© 1999-2013 SmartBrief, Inc.® Legal Information